CannPal Animal Therapeutics Limited (“CannPal”) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. The Company listed on the Australian Stock Exchange (ASX) in 2017, trading under the ASX ticker “CP1”. CannPal was founded to research, develop and commercialise, regulatory approved medicines derived from the medical cannabis plant to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and animal health markets by developing innovative therapeutics using cannabinoids. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.
For media inquiries, please email firstname.lastname@example.org
Geoff Starr – Non-Executive Chairman
Layton Mills – Managing Director
Max Johnston – Non-Executive Director
Robert Clifford – Non-Executive Director
Dr Kate Adams – Non-Executive Director
Merchant Corporate Advisory
45A Bay Street
Double Bay NSW 2028
Computershare Investor Services Pty Limited
172 St Georges Terrace
Perth WA 6000
Level 4, The Read Buildings
16 Milligan Street
Perth WA 6000
BDO Audit (WA) Pty Ltd
38 Station Street
Subiaco WA 6008
When was the Company founded?
The Company was founded in June 2016.
How can I buy and sell shares?
Cannpal’s shares are traded on the ASX and can be bought or sold through a Licensed Stock Broker. The process of buying or selling shares is explained on the ASX website.
Where can I view the Company prospectus?
You can view the Cannpal prospectus here.
What is the Company's ASX code?
The Company’s ASX code is CP1
Where can I find information about my Shareholdings?
The CannPal share register is managed by Computershare Investor Services Pty Ltd (Computershare). Computershare provides a number of services which can be accessed online. When accessing some information online you may be required to enter your Security Reference Number (SRN) or Holder Identification Number (HIN) as shown on your Issuer Sponsored/CHESS statements and other personal details such as your postcode.
Please contact Computershare if you have any inquiries. It will assist if you can quote your current address together with your Security Reference Number (SRN) or Holder Identification Number (HIN) as shown on your Issuer Sponsored/CHESS statements.
Computershare Investor Services Pty Ltd
The Registrar Computershare Investor Services Pty Ltd
GPO Box 2975
MELBOURNE VIC 3001
Level 11, 172 St George’s Terrace
PERTH WA 6000
Who can I contact about media inquiries?
Is Cannabis legal for animals?
The regulatory environment around cannabis for animals is still very unclear. In all major jurisdictions that we are aware of, medical cannabis for animals is illegal, unless it’s being used for medical research purposes and with the necessary permits.
How can I treat my animal with medical cannabis?
You should always seek professional advice from a veterinarian when treating animals for any illness. Unfortunately we cannot give you advice, but we are working towards having our products scientifically tested, validated and labelled correctly to inform and allow veterinarians to prescribe medical cannabis medications for animals.
When can I buy your products?
CannPal is working with regulatory authorities to validate the safety and efficacy of medical cannabis for use in companion pets. This is an arduous process and involves robust clinical studies that take time. This process in its entirety can take 3 to 4 years and in some cases more.
However medical cannabis is an evolving industry and while we will continue to complete the required safety and efficacy studies to show our products are safe and efficacious for regulatory authorities, we are following the legislative changes closely and should there be an opportunity to enter a legal market earlier than anticipated, we are well placed to do so.
We are also researching the benefits of CBD derived from hemp, which isn’t bound by the same legislative rules as medical cannabis. We hope to be able to market a product derived from the hemp plant as early 2019.
Is cannabis dangerous for pets?
Cannabis can be dangerous for animals when taken incorrectly. Dogs have more cannabinoid receptors than humans and can be very sensitive to THC, the psychoactive cannabinoid in cannabis. If you suspect your dog has consumed marijuana without your supervision, take them to the vet immediately. The following signs indicate that your dog may have consumer too much cannabis:
- Dribbling urine
- Walking like they’re intoxicated
- Beginning to fall over while standing still
- Low heart rate
- Low blood pressure
- Wide, dilated pupils
- Easily startled by sudden sounds
However when consumed in the correct ratios of cannabinoids and dosages, and under medical supervision, cannabis is a wonderful medicine for a range of ailments and we’re working to be able to provide pet owners with safe, standardised and dosage controlled medicines using cannabis.
Where can I view the Company's corporate governance plan?
You can view all the Company’s policies and the corporate governance plan here
|08/08/2018||CannPal enters into MOU with The University of Melbourne|
|02/08/2018||CannPal Receives Ethics Approval for Phase 1B Dog Study|
|27/07/2018||Change of Director's Interest Notice RM Johnston|
|17/07/2018||Appendix 4C - Quarterly 30 June 2018|
|04/07/2018||CannPal Enters into Research Agreement with Eurofins|
|28/06/2018||CannPal Research Collaboration with CSIRO|
|19/06/2018||Non-deal Roadshow Presentation|
|18/06/2018||Market Update on Studies|
|29/05/2018||CannPal Enters into Manufacturing Agreement with JayChem|
|23/04/2018||Appendix 4C - Quarterly 31 March 2018|
|27/03/2018||CannPal Imports Cannabis Oils for Clinical Trial|
|27/02/2018||CannPal Further Bolsters its Research Team|
|20/02/2018||Half Yearly Report and Accounts 31 December 2017|
|19/02/2018||Escrow Share Release 2 March 2018|
|31/01/2018||Appendix 4C - Quarterly Cash Flow Report|
|08/01/2018||Corrected Appendix 3B|